Overview
VitaDAO is a community-owned collective that funds and advances early-stage longevity science – the first decentralized science (DeSci) DAO, launched in June 2021 out of a whitepaper by Tyler Golato and Paul Kohlhaas of Molecule, and since grown into the largest organisation in the field. Its aim is to extend human healthspan by pooling community capital to de-risk translational aging research that traditional grant pipelines and venture funds routinely skip.
VitaDAO operates as a BioDAO within the Bio Protocol ecosystem (the network Molecule grew into), and in August 2024 received a 21 million BIO token allocation from Bio Protocol's bio/acc rewards program in recognition of its founding role – giving it a stake in governing new BioDAO launches and ecosystem incentives.
Governance and the VITA token
$VITA is a governance-only token: it confers no dividend and exists to steer the DAO. Voting happens on Snapshot in a gasless, shielded format – members must hold VITA in an Ethereum wallet, weight scales with the number of tokens held, and results stay hidden until the vote closes so early tallies don't sway later voters. This is textbook token-weighted governance, and it inherits token-weighted governance's core tension: influence tracks holdings, not contribution.
Funding decisions escalate by size. Per the VitaDAO constitution, a request up to ~$2,500 needs sign-off from two working-group representatives; up to ~$10,000 needs a majority of working-group stewards; up to ~$50,000 goes to a public governance-forum poll; and anything larger requires that poll plus a full Snapshot vote. Day-to-day work runs through specialist working groups (dealflow, tokenomics, awareness, legal and more) staffed by community stewards rather than a single executive team.
IP-NFTs and tokenized research
The mechanism that distinguishes VitaDAO from an ordinary grants pool is how it holds what it funds. Rather than handing out cash and walking away, VitaDAO captures the intellectual property of funded projects as IP-NFTs – on-chain assets, built with Molecule's tooling, that the community can govern, license, and commercialise. This turns research IP into a treasury asset the DAO co-owns instead of an outcome it merely sponsors.
VitaDAO went a step further with VITA-FAST, the first IP-NFT to be fractionalised into an ERC-20 IP token. VITA-FAST represents shared ownership of the "Discovering Novel Autophagy Activators" IP-NFT from the Korolchuk Lab at Newcastle University, and its holders directly govern licensing decisions and experiment priorities for that specific research line. A later IP token, VITA-RNA, applied the same pattern to another project. This is tokenomics in its most literal DeSci form: a tradeable claim minted directly against a real, governed research asset.
Funding, Pfizer, and the token-versus-value question
In January 2023 VitaDAO closed a $4.1 million round whose backers included Pfizer Ventures, Shine Capital, L1 Digital, Beaker DAO, Spaceship DAO, and individuals such as Balaji Srinivasan and Joe Betts-LaCroix – following Pfizer's initial $500k VITA purchase in September 2022 that made it the first pharmaceutical company to hold a governance token and vote on a DAO proposal. To date the DAO has funded 31 projects and deployed roughly $4.7M across the drug-development pipeline, generating IP transactions and three spun-out companies.
That commercialisation raised a familiar structural problem. In April 2023 VitaDAO members voted to create a for-profit company to carry assets through the capital-intensive stages a community treasury can't underwrite – the same token-versus-equity split AthenaDAO later reached for with AthenaBIO. A freely-traded governance token's price drifts away from the value of the underlying science, so the DAO governs and sources while a separate legal vehicle holds and commercialises the work.
How Caper approaches this
The token-versus-value gap VitaDAO patches with a for-profit spinout is the seam a caper is built to close. On Caper, contributed capital flows into the caper's own bonding-curve treasury rather than into a free-floating governance token whose price detaches from the work – value accrues to the treasury itself, and members hold a participation-weighted claim on it. Research spending is authorised the way any spend is: a PAYOUT proposal that moves a chosen currency and amount from the treasury to a lab once members vote it through. Voting weight is stake weighted by participation rather than raw token balance, so the people funding the science keep governance coupled to their exposure – and there is no separate equity vehicle to stand up to keep the token's price from wandering off from the value being built.